...
【24h】

Plasma exchange in kidney transplantation: Still a valuable option for nephrotic syndrome recurrence

机译:肾移植中的血浆置换:仍然是肾病综合征复发的重要选择

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Abstract About 30 of the cases of steroid resistant nephrotic syndrome display a genetically determined disease and will not recur after kidney transplant; the other cases with fully or partially immunological pathogenesis display a high risk of post transplant recurrence. Although lots of studies were carried out in the last 50 years the pathogenetic mechanism is still obscure and the therapeutic approach mostly empirical. The cornerstones principles of the therapies are based on removal of a still undefined “permeability factor” through plasma-exchange or other apheresis techniques and inhibition of its synthesis by the immunological system through different drugs. The probability of successfully inducing persistant remission is nowadays around 30through the different schemes experimented so far which mostly include plasmapheresis. Rituximab in the last years has significantly increased the efficacy of the treatments. Non responders are rapidly evolving to graft loss and will most probably recur also in subsequent transplant. Apart from genetics no other risk factors are predictive for recurrence. >
机译:摘要 约30%的类固醇耐药性肾病综合征病例表现为遗传性疾病,肾移植后不会复发;其他具有完全或部分免疫发病机制的病例显示出移植后复发的高风险。尽管在过去 50 年中进行了大量研究,但发病机制仍然模糊不清,治疗方法大多是经验性的。这些疗法的基石原理是基于通过血浆置换或其他单采技术去除仍未确定的“渗透性因子”,并通过不同的药物抑制免疫系统的合成。如今,通过迄今为止尝试的不同方案(主要包括血浆置换术),成功诱导持续缓解的概率约为 30%。利妥昔单抗在过去几年中显着提高了治疗效果。无反应者正在迅速演变为移植物丢失,并且很可能在随后的移植中也会复发。除遗传学外,没有其他危险因素可以预测复发。]]>

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号